Recent developments include the commercial launch and initial shipments of the Pivot insulin delivery system in the U.S., capital raises through public offerings, and ongoing efforts to expand market presence and reduce operating expenses.

• In June 2026, Modular Medical announced commercial availability and commenced initial shipments of its Pivot insulin delivery system in the United States [N1][S1].
• In April 2026, the company priced a $3.4 million offering at $4.50 per share [N2].
• In March 2026, the company implemented employee layoffs affecting approximately 29% of its workforce to reduce operating expenses by about $3.4 million annually [S21].
• The company has received FDA clearance for its Pivot pump in April 2026 and is focusing commercialization efforts on this product [S1].

The company’s innovative Pivot insulin pump addresses significant shortcomings in existing insulin pump technology by offering a simpler, more affordable, and user-friendly solution. The large market opportunity among insulin-requiring patients who have not adopted pumps due to cost and complexity could support substantial adoption if the company successfully executes its commercialization strategy. FDA clearance and initial commercial shipments mark important milestones. The company’s approach to insurance reimbursement and patient support may facilitate broader market penetration. Cost reduction initiatives and recent capital raises provide resources to advance commercialization efforts.

The company has a history of significant operating losses and faces substantial liquidity risks, with disclosures indicating doubt about its ability to continue as a going concern without additional financing. The company’s stock faces Nasdaq listing compliance risks related to minimum bid price requirements. Commercialization of a novel medical device in a competitive market involves regulatory, reimbursement, and adoption challenges. The company’s ability to scale manufacturing, secure insurance coverage, and achieve market acceptance among a less motivated patient segment remains uncertain. Failure to raise sufficient capital or execute commercialization plans could adversely impact operations and shareholder value.

Modular Medical’s moat is based on its proprietary insulin pump technology that simplifies the user experience and reduces costs compared to existing pumps. The Pivot pump’s tubeless, reusable design addresses key adoption barriers such as complexity, bulkiness, and high cost, targeting a large underserved market segment of 'Almost Pumpers' who have not adopted pumps due to these issues. The company’s focus on streamlining insurance reimbursement and providing clinical support further differentiates its offering. FDA clearances for both MODD1 and Pivot products and ongoing manufacturing partnerships support regulatory and production capabilities. However, the company operates in a competitive medical device market with established players and faces challenges in scaling commercialization and securing reimbursement coverage.

• Liquidity and Going Concern Risk: The company has disclosed substantial doubt about its ability to continue as a going concern due to expected operating losses and cash burn, requiring additional capital raises to fund operations [S2][S7][S8][S9][S10].
• Nasdaq Listing Compliance Risk: The company has received notices from Nasdaq regarding non-compliance with minimum bid price requirements and has been granted extensions to regain compliance, including authorization for a reverse stock split [S2][S7][S9][S13][S14].
• Commercialization Risk: As an early commercial-stage company, Modular Medical faces challenges in scaling sales, marketing, manufacturing, and reimbursement processes for its Pivot insulin pump [S1].
• Market Adoption Risk: The target market includes patients who have historically not adopted insulin pumps due to cost, complexity, and usability barriers; overcoming these objections is critical to adoption [S1].
• Regulatory and Reimbursement Risk: The company must maintain FDA clearance and secure insurance coverage and reimbursement to support product adoption and sales [S1].
• Competitive Risk: The insulin pump market includes established competitors with more mature products and market presence, posing competitive challenges [S1].

• Modular Medical, Inc. is a medical device company focused on designing, developing, and commercializing innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace [S1].
• The company has developed a two-part patch pump system aimed at simplifying insulin delivery and expanding the market beyond highly motivated 'super users' to a broader mass market, including both type 1 and type 2 diabetes patients requiring multiple daily insulin doses [S1].
• The initial product, MODD1, received FDA 510(k) clearance in September 2024, and the company announced first human use in August 2025 [S1].
• The company developed a next-generation tubeless patch pump called Pivot™, which integrates the infusion set under the removable pump into a true tubeless patch, aiming for cost and usability improvements and improved manufacturability [S1].
• The Pivot pump received FDA 510(k) clearance in April 2026 and was commercially launched with initial shipments in the United States in June 2026 [S1].
• The company does not intend to commercialize the MODD1 product and is focusing on the Pivot pump for commercialization [S1].
• Modular Medical aims to expand commercial activities across metropolitan U.S. markets by late 2026 and intends to obtain CE mark clearance for the Pivot product to market in Europe and other international markets, targeting clearance by Q2 2027 [S1].
• The company targets the 'Almost Pumpers' market segment, defined as insulin-requiring people with diabetes who are aware of pumps but have not adopted them due to cost, complexity, and usability issues [S1].
• The company’s research estimates that 43% of Americans with type 1 diabetes have an insulin pump, and 28% of type 1 diabetes patients (44% of those using multiple daily injections) are interested in pump adoption if objections to current products are overcome, representing a significant market opportunity [S1].
• The Pivot pump features include a three-part system (one reusable, two disposable), one-button interface, phone software for advanced users, 90-day reusable pump with 3-day disposable cartridges, no external controller or battery replacement, and a slim, lightweight profile [S1].
• The company’s business model includes simplifying the insurance reimbursement process, providing prescription assistance, streamlined training, and strong clinical support to increase adoption [S1].
• Modular Medical had 51 employees as of March 31, 2026, primarily in research, development, manufacturing, general administration, and sales and marketing [S1].
• The company reported cash and cash equivalents of $6.942 million as of March 31, 2026, current assets of $7.542 million, and current liabilities of $1.873 million, resulting in a current ratio of 4.03 and a cash ratio of 3.71 [S1].
• The company reported a net loss of $28.242 million and basic and diluted EPS of -$12.36 for the fiscal year ended March 31, 2026 [S1].
• Modular Medical has a history of significant operating losses and expects to continue incurring losses as it commercializes its products [S1].
• The company has raised capital through public offerings, including a $3.4 million offering priced at $4.50 per share in April 2026 and a $3.375 million registered direct offering in April 2026 [N2][S20].
• The company has faced liquidity challenges and has disclosed substantial doubt about its ability to continue as a going concern without additional financing [S2][S7][S8][S9][S10][S13][S14].
• The company is listed on Nasdaq but has received notices regarding non-compliance with minimum bid price requirements and has been granted extensions to regain compliance, including authorization to effect a reverse stock split [S2][S7][S9][S13][S14].
• The company has taken cost reduction measures including employee layoffs in March 2026 to reduce operating expenses by approximately $3.4 million annually [S21].
• Recent news includes the pricing of a $3.4 million offering at $4.50 per share in April 2026, the commercial availability and initial shipments of the Pivot insulin delivery system in June 2026, and ongoing efforts to expand market presence [N2][N1].